Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Sir John Bell

- PMLiVE

Wilmington Healthcare appoints new Solutions Director

Kirsty Fryer has been promoted to the role of Solutions Director for Wilmington Healthcare

Wilmington Healthcare

- PMLiVE

NICE recommends Ultomiris for NHS use in patients with rare blood disorders

aHUS is an ultra-rare and life-threatening disease that causes progressive injury to vital organs

Understanding the role of provider collaboratives

Oli Hudson, Content Director at Wilmington Healthcare, takes a look at the new groups of providers that are expected to play a pivotal role in integrating care.

Wilmington Healthcare

- PMLiVE

NICE recommends Keytruda for colorectal cancer patients with rare mutations

Approximately 450 patients in England will now become eligible for this treatment on the NHS

- PMLiVE

Novartis announces delay in UK cholesterol drug study

The delay was caused by recruitment issues during the COVID-19 pandemic

- PMLiVE

NICE sets out plans for ‘ambitious’ five-year strategy

NICE refocuses on reducing health inequalities and accelerating access to the latest and most effective treatments

- PMLiVE

Alexion and NICE agree confidential discount for Ultomiris use on the NHS

NICE said clinical evidence shows Ultomiris is as effective and safe as Alexion's older PNH drug Soliris

How does the government plan to reshape the NHS?

Oli Hudson, of Wilmington Healthcare, explores the government’s new white paper, which proposes key reforms for health and social care

Wilmington Healthcare

- PMLiVE

Fishawack Health unveils an unrivaled global market access and HEOR offering with the acquisition of PRMA Consulting

Fishawack Health bolsters its strong strategic offering by acquiring PRMA Consulting – a global market access and HEOR consulting leader with significant expertise in US, EU, and Asia-Pacific markets

Avalere Health

- PMLiVE

NICE rejects Keytruda for advanced bladder cancer in final guidance

Treatment had been authorised for use in this indication via the Cancer Drugs Fund in 2018

- PMLiVE

Novartis and NHS England reach ‘landmark’ deal for Zolgensma gene therapy for SMA

Children born with SMA type 1 typically have a life expectancy of around two years

- PMLiVE

NICE turns down bluebird bio’s gene therapy Zynteglo

Draft guidance does not recommend routine NHS funding for beta thalassaemia treatment

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links